EP0918542B1 - Verwendung von (meth)acrylsäure-copolymeren zur erhöhung der permeabilität der schleimhaut - Google Patents
Verwendung von (meth)acrylsäure-copolymeren zur erhöhung der permeabilität der schleimhaut Download PDFInfo
- Publication number
- EP0918542B1 EP0918542B1 EP97934501A EP97934501A EP0918542B1 EP 0918542 B1 EP0918542 B1 EP 0918542B1 EP 97934501 A EP97934501 A EP 97934501A EP 97934501 A EP97934501 A EP 97934501A EP 0918542 B1 EP0918542 B1 EP 0918542B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- meth
- acrylic acid
- permeability
- increase
- ethyl acrylate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
Definitions
- the present invention relates to the use of (Meth) acrylic acid-ethyl acrylate copolymers to increase the permeability the mucous membrane.
- Epithelial tissue For the paracellular transport of hydrophilic active substances, in particular those with higher molecular structures, that forms Epithelial tissue is an important barrier to permeation. So-called “tight junctions” (intercellular junctions between neighboring epithelial cells, in the area of which the plasma membranes directly adjacent) ensure that the internal Milieu of an organ is completed by the external. The passive Paracellular permeability of these epithelial cells is determined through the "tight mesh" of the intercellular contact points. An expansion of the "tight junctions" leads to an improved Absorption and thus a higher bioavailability of active ingredients.
- EP-B-410 422 increase by the fact that after the formulation the influence of (meth) acrylic acid / (meth) acrylate copolymers amorphous are available and are therefore more soluble.
- copolymers according to the invention contain acrylic acid as monomers or methacrylic acid, in the form of their free acid, their Salts and / or their anhydrides can be used.
- the monomers are used in the form of their salts for the polymerization, so are the alkaline earth, alkali or ammonium salts or the salts of organic amines are preferred, particularly preferred the alkali or ammonium salts.
- Ethyl acrylate is included as a further comonomer.
- the (meth) acrylic acid-ethyl acrylate comonomer molar ratio can be in copolymer according to the invention can be varied widely. For example it is in the range from 99: 1 to 1:99, preferably from 70:30 to 30:70.
- the copolymers are usually in the form of pharmaceutical Preparations administered together with the active ingredient.
- a pharmaceutical Pharmaceutical form come tablets, extrudates, Granules, pellets, powders, capsules, suppositories, ointments, Suspensions or emulsions are considered, the administration Depending on the area of application, oral, sublingual, buccal, rectal, pulmonary, nasal or over the eye mucosa.
- Preferred dosage forms are a) matrix tablets, b) coated tablets and c) film-coated tablets.
- matrix tablets in which the polymer according to the invention and the active ingredient after intimate mixing are pressed together, make a Dosage form with high potency.
- the dosage forms mentioned above are usually under Addition of fillers, binders, explosives, lubricants or others Excipients manufactured.
- fillers and dry binders serve for tablets Lactose, sucrose, mannitol, sorbitol, microcrystalline cellulose, starch, dicalcium phosphate and Polyglycols.
- Suitable binders for granulation are e.g. Starch, alginates, polyvinyl pyrrolidone and carboxymethyl cellulose.
- Suitable flow regulators are e.g. Starch, talc and Silica.
- As a lubricant in mechanical et al Starch cellulose derivatives and cross-linked polyvinyl pyrrolidone.
- the inventive Copolymers advantageously in neutralized, partially neutralized or unneutralized form.
- the copolymers in unneutralized form so is the presence a base or a proton acceptor that either from another excipient and / or directly from the active ingredient exists, often advantageous.
- copolymers are prepared in accordance with those in the literature known processes such as solvent polymerization, Suspension polymerization or emulsion polymerization, emulsion polymerization is preferred.
- the emulsion polymerization is carried out in the usual manner
- Use of initiators such as peroxo or azo compounds, for example dibenzoyl oxide, t-butyl perpivalate, t-butyl per-2-ethylhexanoate, Di-t-butyl peroxide, t-butyl hydroperoxide, Alkali metal or ammonium persulfates, azo-bis-isobutyronitrile, 2,2'-azobis (2-methylbutyronitrile), 2,2'-azobis (2,4-dimethylvaleronitrile), 1,1'-azo-bis- (1-cyclohexane carbonitrile), 2,2'-azobis (2-amidinopropane) salts, 4,4'-azobis (4-cyanovaleric acid) or 2- (carbamoylazo) isobutyronitrile etc., hydrogen peroxide or redox initiators.
- the initiators are usually in Amounts up to 10, preferably 0.
- the polymerization is carried out in the presence of one for these purposes usual emulsifier and / or protective colloid performed.
- Suitable protective colloids are, for example, polyvinyl alcohols, Cellulose derivatives or polyvinyl pyrrolidones.
- the emulsifiers can be anionic, cationic or non-ionic in nature.
- Suitable emulsifiers are, for example, ethoxylated mono-, di- and Trialkylphenols, ethoxylated fatty alcohols or sorbitan esters, Alkali and ammonium salts of alkyl sulfates or alkyl ether sulfates, of alkyl sulfonic acids, of lignosulfonic acid and of alkylarylsulfonic acids or alkyldiphenyloxidesulfonates.
- the emulsion polymerization is usually carried out in the absence of oxygen at temperatures in the range of 20 to 200 ° C.
- the Polymerization can be carried out batchwise or continuously become.
- At least some of the monomers are metered in, Initiators and optionally regulators, such as aldehydes, halogen compounds or sulfur compounds, for example formaldehyde, Acetaldehyde, bromotrichloromethane, mercaptoethanol, thioglycolic acid or dodecyl mercaptan, during the polymerization evenly into the reaction vessel.
- Initiators and optionally regulators such as aldehydes, halogen compounds or sulfur compounds, for example formaldehyde, Acetaldehyde, bromotrichloromethane, mercaptoethanol, thioglycolic acid or dodecyl mercaptan
- copolymers with an average molecular weight received from 50,000 to 2 million.
- copolymers with a medium Molecular weight from 20,000 to 1,500,000, especially 120,000 up to 400,000 particularly suitable.
- Caco-2 cells were at 37 ° C in DMEM (Dulbecco's Modified Eagle's Medium, Gibco BRL, Eggenstein, Germany) with 10% FCS (fetal calf serum), 1% L-glutamine and 4.5 mg / ml glucose at 5% Cultivated CO 2 and 95% relative humidity. After trypsinization, the cells were sown at a density of 3 ⁇ 10 5 cells / cm 2 on Transwell polycarbonate filters. Cells between the thirtieth and fiftieth passages were used for monolayer formation. The monolayers were used in the experiment after 15 to 21 days (medium change: every three days) after sowing the cells.
- the Caco-2 cell tissue was in the Transwell filter cartridges washed with PBS (Phosphate buffer saline). The apical compartment was then buffered with EBSS (Earl's Saline solution, pH 6), the basolateral compartment with DMEM refilled.
- PBS Phosphate buffer saline
- EBSS Error's Saline solution, pH 6
- a film coating with methacrylic acid-ethyl acrylate copolymer was applied to these curved tablets in a horizontal drum coater of the Accela-Cota type (from Manesty) at an inlet air temperature of 50 ° C.
- the film coating dispersion had the following composition: Titanium dioxide 0.5% by weight talc 2% by weight Sicovit® Red 30 0.5% by weight Kollidon® 30 0.5% by weight Methacrylic acid-ethyl acrylate Copolymer (1: 1), neutralized to pH 7 15% by weight triethylcitrate 1.5% by weight water 80% by weight
- the order quantity for 5000 g curved tablets was 1680.8 g Film coating dispersion.
- Methacrylic acid-ethyl acrylate copolymer (1: 1) neutralized to pH 7 347.5 mg Aerosil 200® 3.5 mg Kollidon® CL 6 mg magnesium stearate 3 mg tablet mass 610 mg
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
Abstract
Description
Kontrolle | Kollicoat® MAE 30 D | ||||
0.5% | 1.0% | 1.5% | 3.0% | ||
Permeationsgeschwindigkeit [(cm/sec)*10-8] | |||||
Testsubstanz | |||||
Fluorescein-Biotin | 2.3 | 2.3 | 5.8 | 20 | - |
Dextran-FITC 4400 | 0.8 | - | 9.6 | - | 935 |
Dextran-FITC 11000 | 2.3 | - | 17.0 | - | 769 |
C22H32N6O4 | 56 | 79 | 94 | 280 | - |
Kontrolle | Eudragit® L 100 | ||||
2.0% | |||||
Permeationsgeschwindigkeit [(cm/sec).10-8] | |||||
Testsubstanz | |||||
Fluorescein-Biotin | 2.3 | 4.8 | |||
C22H32N6O4 | 56 | 104 | |||
Kontrolle | Eudragit® S 100 | ||||
2.0% | |||||
Permeationsgeschwindigkeit [(cm/sec).10-8] | |||||
Testsubstanz | |||||
Fluorescein-Biotin | 2.3 | 7.1 | |||
C22H32N6O4 | 56 | 103 | |||
Atenolol | 50 mg |
Ludipress® | 50 mg |
Methacrylsäure-Ethylacrylat Copolymer (1:1), neutralisiert auf pH 7 |
146,5 mg |
Aerosil 200® | 2 mg |
Magnesiumstearat | 1,5 mg |
Tablettenmasse | 250 mg |
Titandioxid | 0,5 Gew.-% |
Talkum | 2 Gew.-% |
Sicovit® Rot 30 | 0,5 Gew.-% |
Kollidon® 30 | 0,5 Gew.-% |
Methacrylsäure-Ethylacrylat Copolymer (1:1), neutralisiert auf pH 7 | 15 Gew.-% |
Triethylcitrat | 1,5 Gew.-% |
Wasser | 80 Gew.-% |
Propranolol-HCl | 160 mg |
Methacrylsäure-Ethylacrylat Copolymer (1:1), neutralisiert auf pH 7 |
190 mg |
Aerosil 200® | 3,4 mg |
Magnesiumstearat | 1,6 mg |
Tablettenmasse | 355 mg |
Furosemid | 1 mg |
Methacrylsäure-Ethylacrylat Copolymer (1:1), neutralisiert auf pH 7 |
5,95 mg |
Magnesiumstearat | 0,05 mg |
Tablettenmasse | 7 mg |
Methyldopa | 250 mg |
Methacrylsäure-Ethylacrylat Copolymer (1:1), neutralisiert auf pH 7 | 347,5 mg |
Aerosil 200® | 3,5 mg |
Kollidon® CL | 6 mg |
Magnesiumstearat | 3 mg |
Tablettenmasse | 610 mg |
S-Adenosylmethionin | 100 mg |
Methacrylsäure-Ethylacrylat Copolymer (1:1), neutralisiert auf pH 7 | 700 mg |
Mannit | 200 mg |
Aspartame | 3 mg |
Orangenaroma | 5 mg |
Kollidon® VA 64 | 37 mg |
Aerosil 200® | 5 mg |
Magnesiumstearat | 5 mg |
Tablettenmasse | 1055 mg |
Claims (3)
- Verwendung von (Meth)acrylsäure-Ethylacrylat-Copolymeren zur Herstellung von Arzneimitteln zur Erhöhung der Permeabilität der Schleimhaut.
- Verwendung nach Anspruch 1 dadurch gekennzeichnet, daß das (Meth)acrylsäure:Comonomer-Molverhältnis von 99:1 bis 1:99 variiert.
- Verwendung gemäß den Ansprüchen 1 oder 2, dadurch gekennzeichnet, daß die Arzneimittel zur Verabreichung in oraler, fester Form geeignet sind.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19631084 | 1996-08-01 | ||
DE19631084A DE19631084A1 (de) | 1996-08-01 | 1996-08-01 | Verwendung von (Meth)acrylsäure-Copolymeren zur Erhöhung der Permeabilität der Schleimhaut |
PCT/EP1997/003899 WO1998005360A2 (de) | 1996-08-01 | 1997-07-21 | Verwendung von (meth)acrylsäure-copolymeren zur erhöhung der permeabilität der schleimhaut |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0918542A2 EP0918542A2 (de) | 1999-06-02 |
EP0918542B1 true EP0918542B1 (de) | 2004-05-06 |
Family
ID=7801501
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP97934501A Expired - Lifetime EP0918542B1 (de) | 1996-08-01 | 1997-07-21 | Verwendung von (meth)acrylsäure-copolymeren zur erhöhung der permeabilität der schleimhaut |
Country Status (11)
Country | Link |
---|---|
US (1) | US6555124B1 (de) |
EP (1) | EP0918542B1 (de) |
JP (1) | JP2000515159A (de) |
KR (1) | KR20000029736A (de) |
CN (1) | CN1182872C (de) |
AU (1) | AU3769197A (de) |
BR (1) | BR9710889A (de) |
DE (2) | DE19631084A1 (de) |
ES (1) | ES2221060T3 (de) |
WO (1) | WO1998005360A2 (de) |
ZA (1) | ZA976846B (de) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20020004995A (ko) * | 1999-04-09 | 2002-01-16 | 스타르크, 카르크 | 트롬빈 억제제의 프로드럭 |
KR100452972B1 (ko) * | 2000-05-16 | 2004-10-14 | 주식회사 삼양사 | 경피투여용 하이드로젤 조성물 |
DE60226012T2 (de) * | 2001-03-05 | 2009-05-14 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | Geschmacksmaskierte pharmazeutische formulierungen |
US8206738B2 (en) | 2001-05-01 | 2012-06-26 | Corium International, Inc. | Hydrogel compositions with an erodible backing member |
CA2445086C (en) * | 2001-05-01 | 2008-04-08 | A.V. Topchiev Institute Of Petrochemical Synthesis | Hydrogel compositions |
US8840918B2 (en) | 2001-05-01 | 2014-09-23 | A. V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences | Hydrogel compositions for tooth whitening |
TWI355276B (en) * | 2003-01-14 | 2012-01-01 | Akira Tsuji | Gastrointestinal absorption enhancer mediated by p |
WO2006026504A2 (en) * | 2004-08-27 | 2006-03-09 | Spherics, Inc. | Mucoadhesive oral formulations of high permeability, high solubility drugs |
LT5465B (lt) | 2006-03-29 | 2008-01-25 | Bugajec, Evgenij | Koaksialinis uždegimo kabelis |
US20090088404A1 (en) * | 2007-01-31 | 2009-04-02 | Methylation Sciences International Srl | Extended Release Pharmaceutical Formulations of S-Adenosylmethionine |
AU2010204986B2 (en) | 2009-01-14 | 2016-06-02 | Corium International, Inc. | Transdermal administration of tamsulosin |
US8329208B2 (en) | 2009-07-28 | 2012-12-11 | Methylation Sciences International Srl | Pharmacokinetics of S-adenosylmethionine formulations |
US20110027342A1 (en) * | 2009-07-28 | 2011-02-03 | Msi Methylation Sciences, Inc. | S-adenosylmethionine formulations with enhanced bioavailability |
WO2011115974A1 (en) | 2010-03-15 | 2011-09-22 | Indiana University Research And Technology Corporation | Engineered lumenized vascular networks and support matrix |
WO2019105519A1 (en) | 2017-12-03 | 2019-06-06 | Abd Elaal Nasser Kamal | Tranexamic acid coated or eluted uterine balloon and co-attached cervical shutter in the management of postpartum haemorrhage |
KR20220128362A (ko) | 2019-12-27 | 2022-09-20 | 에벨로 바이오사이언시즈, 인크. | 박테리아 및 미생물 세포외 소포체를 함유하는 고체 투여 형태 |
WO2021146523A1 (en) | 2020-01-17 | 2021-07-22 | Evelo Biosciences, Inc. | Solid dosage forms with improved disintegration profiles |
EP4135670A1 (de) | 2020-04-17 | 2023-02-22 | Evelo Biosciences, Inc. | Feste darreichungsformen mit verbesserten zerfallsprofilen |
AU2021342481A1 (en) | 2020-09-18 | 2023-05-04 | Evelo Biosciences, Inc. | Solid dosage forms of bacteria |
WO2022061123A1 (en) | 2020-09-21 | 2022-03-24 | Evelo Biosciences, Inc. | Solid dosage forms with improved disintegration profiles |
KR20230127985A (ko) | 2020-10-29 | 2023-09-01 | 에벨로 바이오사이언시즈, 인크. | 스피룰리나 성분을 포함하는 조성물 |
EP4259806A1 (de) | 2020-12-14 | 2023-10-18 | Evelo Biosciences, Inc. | Extrazelluläre vesikelzubereitungen |
EP4267154A1 (de) | 2020-12-22 | 2023-11-01 | Evelo Biosciences, Inc. | Zusammensetzungen mit tierhämoglobin |
KR20230137968A (ko) | 2021-01-26 | 2023-10-05 | 에벨로 바이오사이언시즈, 인크. | 프레보텔라 세포외 소포체 제제 |
EP4297762A1 (de) | 2021-02-26 | 2024-01-03 | Evelo Biosciences, Inc. | Zusammensetzungen und verfahren zur reduzierung der cytokinexpression |
TW202302125A (zh) | 2021-03-05 | 2023-01-16 | 美商艾弗洛生物科技股份有限公司 | 固體劑型 |
TW202304415A (zh) | 2021-04-08 | 2023-02-01 | 美商艾弗洛生物科技股份有限公司 | 含有細菌的藥物製劑 |
WO2022221183A1 (en) | 2021-04-12 | 2022-10-20 | Evelo Biosciences, Inc. | Fournierella extracellular vesicle preparations |
WO2022251166A2 (en) | 2021-05-25 | 2022-12-01 | Evelo Biosciences, Inc. | Bacterial compositions comprising soy hemoglobin |
WO2023049268A1 (en) | 2021-09-24 | 2023-03-30 | Evelo Biosciences, Inc. | Solid dosage forms containing bacteria and microbial extracellular vesicles |
WO2023114293A1 (en) | 2021-12-14 | 2023-06-22 | Evelo Biosciences, Inc. | Extracellular vesicle assays |
WO2023114295A1 (en) | 2021-12-14 | 2023-06-22 | Evelo Biosciences, Inc. | Veillonella parvula bacteria extracellular vesicle preparations |
WO2023114300A1 (en) | 2021-12-14 | 2023-06-22 | Evelo Biosciences, Inc. | Fournierella massiliensis bacteria extracellular vesicle preparations |
WO2023146843A1 (en) | 2022-01-25 | 2023-08-03 | Evelo Biosciences, Inc. | Extracellular vesicle compositions and methods of use |
WO2023183396A1 (en) | 2022-03-22 | 2023-09-28 | Evelo Biosciences, Inc. | Compositions and methods of treating inflammation using prevotella histicola |
WO2023200837A1 (en) | 2022-04-13 | 2023-10-19 | Evelo Biosciences, Inc. | Compositions and methods of treating inflammation using prevotella histicola |
WO2023239728A1 (en) | 2022-06-07 | 2023-12-14 | Evelo Biosciences, Inc. | Compositions and methods of treating inflammation using prevotella histicola extracellular vesicles |
WO2024102226A1 (en) | 2022-10-14 | 2024-05-16 | Evelo Biosciences, Inc. | Methods for assaying drug substances and drug products by using cell lines with nf-kb- inducible reporter genes |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4003991A (en) * | 1974-08-27 | 1977-01-18 | National Patent Development Corporation | Ophthalmic formulation |
GB1596166A (en) | 1977-11-14 | 1981-08-19 | Egyt Gyogyszervegyeszeti Gyar | Pharmaceutical compositions |
CH637017A5 (en) | 1977-11-21 | 1983-07-15 | Egyt Gyogyszervegyeszeti Gyar | Process for the preparation of pharmaceutical active compounds having a depot effect |
US4704284A (en) * | 1982-08-12 | 1987-11-03 | Pfizer Inc. | Long-acting matrix tablet formulations |
DE3678640D1 (de) * | 1985-08-26 | 1991-05-16 | Procter & Gamble | Geschmack abdeckende zusammensetzungen. |
US4760093A (en) | 1986-10-21 | 1988-07-26 | American Home Products Corporation (Del.) | Spray dried acetaminophen |
US4968508A (en) * | 1987-02-27 | 1990-11-06 | Eli Lilly And Company | Sustained release matrix |
JPH0347134A (ja) | 1989-03-08 | 1991-02-28 | Hoechst Japan Ltd | ヒドロゲル製剤およびキセロゲル製剤の製造法 |
AU644815B2 (en) | 1989-09-08 | 1993-12-23 | Ortho-Mcneil Pharmaceutical, Inc. | Solid matrix system for transdermal drug delivery |
DE3930733A1 (de) | 1989-09-14 | 1991-03-28 | Roehm Gmbh | Verfahren zur herstellung eines komplexierten arzneimittels |
CA2055522A1 (en) * | 1990-12-12 | 1992-06-13 | Masako Andoh | Microspheres for ophthalmic use |
EP0518468B1 (de) | 1991-05-09 | 1999-06-30 | Neurim Pharmaceuticals (1991) Limited | Melatonin enthaltende Arzneimittel |
DE4138513A1 (de) * | 1991-11-23 | 1993-05-27 | Basf Ag | Feste pharmazeutische retardform |
US5376384A (en) * | 1992-12-23 | 1994-12-27 | Kinaform Technology, Inc. | Delayed, sustained-release pharmaceutical preparation |
US5744155A (en) * | 1993-08-13 | 1998-04-28 | Friedman; Doron | Bioadhesive emulsion preparations for enhanced drug delivery |
IT1274241B (it) * | 1993-12-03 | 1997-07-15 | Smithkline Beecham Farma | Complessi agente terapeutico/matrice polimerica dotati di migliorate caratteristiche di sapore e composizioni farmaceutiche che li contengono |
AT403988B (de) | 1994-05-18 | 1998-07-27 | Lannacher Heilmittel | Festes orales retardpräparat |
DE19631085A1 (de) * | 1996-08-01 | 1998-02-05 | Basf Ag | Verwendung von (Meth)acrylsäure-Maleinsäure-Copolymeren zur Verbesserung der Permeabilität der Schleimhaut |
-
1996
- 1996-08-01 DE DE19631084A patent/DE19631084A1/de not_active Withdrawn
-
1997
- 1997-07-21 WO PCT/EP1997/003899 patent/WO1998005360A2/de not_active Application Discontinuation
- 1997-07-21 BR BR9710889A patent/BR9710889A/pt not_active Application Discontinuation
- 1997-07-21 EP EP97934501A patent/EP0918542B1/de not_active Expired - Lifetime
- 1997-07-21 US US09/230,741 patent/US6555124B1/en not_active Expired - Fee Related
- 1997-07-21 DE DE59711600T patent/DE59711600D1/de not_active Expired - Lifetime
- 1997-07-21 JP JP10507524A patent/JP2000515159A/ja not_active Withdrawn
- 1997-07-21 ES ES97934501T patent/ES2221060T3/es not_active Expired - Lifetime
- 1997-07-21 CN CNB971969647A patent/CN1182872C/zh not_active Expired - Fee Related
- 1997-07-21 AU AU37691/97A patent/AU3769197A/en not_active Abandoned
- 1997-07-21 KR KR1019997000840A patent/KR20000029736A/ko not_active Application Discontinuation
- 1997-07-31 ZA ZA976846A patent/ZA976846B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
DE19631084A1 (de) | 1998-02-05 |
AU3769197A (en) | 1998-02-25 |
US6555124B1 (en) | 2003-04-29 |
ES2221060T3 (es) | 2004-12-16 |
WO1998005360A2 (de) | 1998-02-12 |
WO1998005360A3 (de) | 1998-05-07 |
CN1182872C (zh) | 2005-01-05 |
EP0918542A2 (de) | 1999-06-02 |
JP2000515159A (ja) | 2000-11-14 |
KR20000029736A (ko) | 2000-05-25 |
DE59711600D1 (de) | 2004-06-09 |
CN1226834A (zh) | 1999-08-25 |
ZA976846B (en) | 1999-02-01 |
BR9710889A (pt) | 1999-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0918542B1 (de) | Verwendung von (meth)acrylsäure-copolymeren zur erhöhung der permeabilität der schleimhaut | |
DE69917866T2 (de) | Bupropionhydrochlorid enthaltende Tabletten mit gesteuerter Wirkstoffabgabe | |
EP1124541B1 (de) | Verwendung von wasserlöslichen oder wasserdispergierbaren polyether-haltigen pfropfpolymerisaten als überzugsmittel, bindemittel und/oder filmbildender hilfsstoff in pharmazeutischen darreichungsformen | |
EP0545209B1 (de) | Redispergierbares Dispersionspulver aus N-Vinylpyrrolidon-Vinylacetat-Copolymerisat, dessen Herstellung und Verwendung | |
DE60202662T2 (de) | NEUE FILMBESCHICHTUNG enthaltend ein Äthylacrylate/Methylmethacrylate-copolymer und Polyvinylacetat | |
EP0760654B1 (de) | Verfahren zur herstellung von wirkstoffzubereitungen in form einer festen lösung des wirkstoffs in einer polymermatrix | |
EP0704208B1 (de) | Überzugs- und Bindemittel für Arzneiformen sowie damit hergestellte Arzneiform | |
EP0868912B1 (de) | Verwendung von redispergierbaren Polymerpulvern oder Polymergranulaten zum Überziehen von pharmazeutischen oder agrochemischen Darreichungsformen | |
EP0868910B1 (de) | Verwendung von redispergierbaren Polymerpulvern oder Polymergranulaten als Bindemittel zur Herstellung von festen pharmazeutischen Darreichungsformen | |
EP0058765B1 (de) | In Magensaft lösliche oder quellbare Überzugsmasse und ihre Verwendung in einem Verfahren zum Überziehen von Arzneiformen | |
EP1200521A1 (de) | Dispersion mit nichtionischem emulgator | |
DE10208335A1 (de) | Arzneiform und Verfahren zu ihrer Herstellung | |
EP2164462A2 (de) | Pharmazeutische formulierung für die herstellung von schnell zerfallenden tabletten | |
DE19961897A1 (de) | Verwendung eines Filmüberzuges als geschmacksmaskierendes Coating von pharmazeutischen Darreichungsformen | |
DE602006000819T2 (de) | Dipyridamol enthaltende Zusammensetzungen mit verlängerter Freisetzung und Verfahren zu deren Herstellung | |
DD298205A5 (de) | Verfahren zum herstellen von langzeitwirkenden arzneimittelzubereitungen | |
EP1001757A1 (de) | Schnell wirksames analgeticum | |
EP0128483A2 (de) | Neue galenische Zubereitungsformen von oralen Antidiabetika und Verfahren zu ihrer Herstellung | |
DE1467781A1 (de) | Verfahren zur Herstellung von Dragees mit verlaengerter Wirkstofffreigabe | |
DE4220782A1 (de) | Verfahren zur Herstellung von festen pharmazeutischen Retardformen | |
DE102011051653A1 (de) | Quellfähige Manteltablette | |
EP0821965B1 (de) | Verwendung von (Meth)arcylsäure-Maleinsäure-Copolymeren zur Verbesserung der Permeabilität der Schleimhaut | |
CH621940A5 (en) | Process for the production of a pharmaceutical composition with delayed release of active ingredient | |
DE2718260A1 (de) | Therapeutische zusammensetzung und verfahren zur herstellung einer tablette | |
DD273772A5 (de) | Waessrige dispersion eines umhuellungsmittels fur arzneistoffe |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19990108 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): CH DE ES FR GB IT LI NL |
|
17Q | First examination report despatched |
Effective date: 20010625 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): CH DE ES FR GB IT LI NL |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D Free format text: NOT ENGLISH |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REF | Corresponds to: |
Ref document number: 59711600 Country of ref document: DE Date of ref document: 20040609 Kind code of ref document: P |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20040704 Year of fee payment: 8 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20040708 Year of fee payment: 8 |
|
GBT | Gb: translation of ep patent filed (gb section 77(6)(a)/1977) |
Effective date: 20040623 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20040719 Year of fee payment: 8 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20040721 Year of fee payment: 8 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20040729 Year of fee payment: 8 Ref country code: CH Payment date: 20040729 Year of fee payment: 8 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2221060 Country of ref document: ES Kind code of ref document: T3 |
|
ET | Fr: translation filed | ||
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20050208 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20050721 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20050721 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20050722 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20050731 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20050731 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF THE APPLICANT RENOUNCES Effective date: 20050813 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20060201 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20050721 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20060331 |
|
NLV4 | Nl: lapsed or anulled due to non-payment of the annual fee |
Effective date: 20060201 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20060331 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20050722 |